An interventional study of Dapagliflozin and Empagliflozin (EMPA) in Diabetic Nephropathies, Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic, sponsored by Lahore General Hospital. Completed at 1 site in Pakistan. Open to participants aged 20 Months to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Lahore General Hospital · Not applicable, Interventional, and Treatment
This study was designed to compare empagliflozin and dapagliflozin in reducing protein leakage into the urine in adults with type 2 diabetes and chronic kidney disease. It examined whether the two medicines differed in their effects on urine protein levels. Blood sugar control, kidney function, treatment costs, and side effects were also selected for comparison.
The study was planned as a randomized controlled trial at the Nephrology Department of Lahore General Hospital, Lahore, Pakistan. The planned sample comprised 116 men and women aged 20-70 years who had increased urine albumin levels and an estimated glomerular filtration rate, a measure of kidney filtration, above 45 mL/min/1.73 m². Participants were to be assigned by a lottery method to two equal groups of 58 patients. One group was to receive dapagliflozin 5 mg once daily, and the other empagliflozin 10 mg once daily.
Assessments were scheduled before treatment and after two and four months. The main assessment was the change in the urine albumin-to-creatinine ratio, which measured the amount of albumin, a blood protein, leaking into the urine. Other assessments included blood tests for kidney function and average blood sugar levels. Treatment costs and side effects, including low blood sugar, urinary tract infections, oral thrush, dehydration, allergic reactions, body pains, and kidney failure, were also included in the follow-up plan. The study aimed to compare the benefits, safety, and costs of these treatments in the selected patients.
544 studies on the registry are indexed under Diabetic Nephropathies; 107 are open to participants now.
This study's enrollment of 116 is above the median of 80 across 385 interventional studies indexed under Diabetic Nephropathies.
Browse Diabetic Nephropathies studies →Lahore General Hospital is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients were assigned to dapagliflozin 5 mg orally once daily for four months, alongside their existing treatment for diabetes and hypertension.
Drug: Dapagliflozin
Patients were assigned to empagliflozin 10 mg orally once daily for four months, alongside their existing treatment for diabetes and hypertension.
Drug: Empagliflozin (EMPA)
Dapagliflozin tablet, 5 mg orally once daily for four months.
Empagliflozin tablet, 10 mg orally once daily for four months.
Change in urinary albumin-to-creatinine ratio
Change from baseline in urinary albumin-to-creatinine ratio, measured in mg/g using a spot urine sample. Changes were compared between the dapagliflozin and empagliflozin groups to assess reduction in albuminuria.
Time frame: Baseline, 2 months, and 4 months
Change in glycated haemoglobin
Change from baseline in glycated haemoglobin, measured as a percentage, was compared between the treatment groups to assess glycaemic control.
Time frame: Baseline, 2 months, and 4 months
Change in estimated glomerular filtration rate
Change from baseline in estimated glomerular filtration rate, expressed in mL/min/1.73 m² and calculated using the Modification of Diet in Renal Disease equation, was compared between the treatment groups.
Time frame: Baseline, 2 months, and 4 months
Treatment cost per participant
Treatment expenditure per participant, expressed in Pakistani rupees, was recorded over the four-month treatment period and compared between the treatment groups.
Time frame: From treatment initiation through 4 months
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin
Lahore General Hospital